TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Epinephrine/ Phenylephrine for Preventing the Postreperfusion Syndrome During Reperfusion in Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- adults scheduled to undergo liver transplantation~Exclusion Criteria:~- pediatric liver transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- phenylephrine (Type: EXPERIMENTAL): 100 mcg of phenylephrine is administered at the time of reperfusion
- epinephrine (Type: EXPERIMENTAL): 10 mcg of epinephrine is administered iv at the time of reperfusion
- control (Type: PLACEBO_COMPARATOR): 10 ml of normal saline is administered at the time of reperfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic Hepatitis B, documented by Clinical history compatible with chronic HBV~Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Patient is pregnant or breastfeeding~* Patient is co infected with hepatitis C virus (HCV), hepatitis D virus (HDV), HIV-1 or HIV-2.~* Patient previously received lamivudine or an investigational anti-HBV nucleoside or nucleotide analog at any time~* Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study~Other protocol defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with Type 1 Diabetes mellitus.~* Participants treated with multiple daily injections using basal insulin analog once daily and rapid acting insulin analogs for at least one year.~* HbA1c greater than or equal to (\>=) 7 percent (%) (53 millimoles per mole \[mmol/mol\]) and less than or equal to (\<=) 10% (86 mmol/mol) at screening.~Exclusion criteria:~* Participants not on stable dose of basal insulin analog.~* Participants having received Toujeo or Tresiba as basal insulin within 30 days prior to screening.~* Participants not having used the same insulins (both basal and rapid) within 30 days prior to screening.~* Participants having received basal insulin dose \>= 0.6 units per kilogram body weight within 30 days prior to screening.~* Participants having received any glucose lowering drugs (including any premixed insulins, human regular insulin as mealtime insulins, any others injectable or oral), other than basal and rapid insulin analogs, within 3 months prior to screening.~* End stage renal disease or on renal replacement treatment.~* Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery.~* Body weight change \>=5 kilogram within 3 months prior to screening.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Toujeo (Type: EXPERIMENTAL): Toujeo (Insulin Glargine, 300 U/ml) subcutaneous (SC) injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
- Tresiba (Type: ACTIVE_COMPARATOR): Tresiba (Insulin Degludec, 100U/ml) SC injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type II diabetes~* Overt proteinuria defined by urinary albumin excretion \> 300 mg/24 hr in 2 consecutive determinations despite treatment with highest FDA recommended doses of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker for at least 6 months.~* Treatment of hyperglycemia with (but not limited to) an oral hypoglycemic agent or insulin (If a thiazolidinedione is used, stable dose for at least 6 months)~* Treatment of hypercholesterolemia with (but not limited to) one medication from the class statins~* Presence of diabetic retinopathy~* Signing informed consent~Exclusion Criteria:~* Type I diabetes~* Advanced chronic kidney disease defined by estimated GFR \< 30 ml/min/1.73 m2~* Severely uncontrolled diabetes defined by HbA1C \> 10%~* Uncontrolled hypertension defined by SBP \>160 mmHg or DBP \>100 mmHg despite antihypertensive therapy~* Secondary forms of hypertension with defined etiology other than diabetes mellitus~* Other renal diseases~* History of solid organ transplantation~* Chronic Heart Failure with NYHA class III or IV~* Active infection~* Pregnancy~* Use of one of the following medications within 2 months prior to enrollment in the study:~  * Non-steroidal anti-inflammatory agents~ * Antioxidants supplements including: vitamin E, vitamin C, N-acetyl- cysteine (NAC), Pentoxyfilline, Lipoic acid, Fish-oil extracts (omega-3 fatty acids), Soy extracts (isoflavones), Green-tea preparations, Pomegranate extracts, Grape extracts~* Active malignancy~* Hepatitis virus or Human Immunodeficiency virus infections~* History of drug or alcohol dependency~* Cigarette smoking~* Psychiatric or neurological condition, preventing aware consent to the study and/or adherence to the study protocol

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): 1 tablet 3 times daily
- Milk Thistle extract (Type: EXPERIMENTAL): 1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HD17 for Intermediate Stage Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hodgkin Lymphoma~* CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included)~* large mediastinal mass (\>1/3 of maximum transverse thorax diameter)~* extranodal involvement~* elevated ESR~* 3 or more involved nodal areas~* written informed consent~Exclusion Criteria:~* Leucocytes \<3000/µl~* Platelets \< 100000/µl~* Hodgkin Lymphoma as composite lymphoma~* Activity Index (WHO) \>2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): 2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
- Arm B (Type: EXPERIMENTAL): 2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Responsive e-Health Intervention for Perinatal Depression in Healthcare Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant or postpartum~* have elevated Edinburgh Postnatal Depression Scale (EPDS) of ≥ 12~* access to broadband internet and a computer at home (desktop, laptop, tablet) or a smartphone (iOS or Android)~* English language proficiency sufficient to enable completion of the informed consent and to engage in all study activities that are delivered in English~Exclusion Criteria:~* Women assessed with active suicidal ideation will be excluded and provided with immediate psychiatric care consistent with NorthShore's established safety protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment As Usual + MMB 2.0 (Type: OTHER): Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
- Treatment As Usual Only (Type: OTHER): NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified NSCLC~* Not eligible for Radiochemotherapy or patient refuses chemotherapy~* FeV1 \>1.5 L or min. 50%~* KPI \>= 70%~* Life expectancy \> 6 months~* Weight loss less than 10% of body weight in 12 months~* Compliance~* Adequate blood counts (LC \> 3000 x 10\^3/ml, Tc \>100000 x 10\^3/ml, Hb \> 10 g/dl)~* Effective contraception~Amendment 1/07: FeV1 \>1.2 L or min 40%~Exclusion Criteria:~* Active infection~* Reduced liver function~* Vena cava superior syndrome~* Malignant pleural effusion~* Pregnancy or breast feeding~* Additional serious systemic disease~* Secondary malignancy (except carcinoma in situ of the cervix, basalioma of the skin, secondary cancer in remission for \> 5 years)~* Known allergies against proteins~* History of former antibody therapy~* Allergy against i.v. contrast agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged greater than or equal to 18 years at the time of signing informed consent.~* BMI greater than or equal to 30.0 kg/m\^2~* Prediabetes defined as at least one of the following:~  * HbA1c between 6.0 and 6.4 percent (42 and 47 mmol/mol) (both inclusive) as measured by central laboratory at screening.~ * FPG between 5.5 and 6.9 mmol/L (99 and 125 mg/dL) (both inclusive) as measured by central laboratory at screening.~Exclusion Criteria:~* History of type 1 or type 2 diabetes.~* Treatment with glucose-lowering agent(s) within 90 days before screening.~* HbA1c greater than or equal to 6.5 percent (greater than or equal to 48 mmol/mol) as measured by central laboratory at screening.~* FPG greater than or equal to 7.0mmol/L (126 mg/dL) as measured by central laboratory at screening.~A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records.~* Treatment with any medication for the indication of obesity within the past 90 days before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks
- Placebo (semaglutide) (Type: PLACEBO_COMPARATOR): Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to provide a written informed consent~2. Male or female~3. Subjects requiring elective general anesthesia surgery~4. Conform to the ASA Physical Status Classification~5. Meet the weight standard~Exclusion Criteria:~1. Not suitable for nasal spray~2. Pediatric populations requiring special care or court/social welfare supervision~3. Subjects who had been under general anesthesia when they were randomized~4. Subjects with a history of mental illness and a history of cognitive impairment epilepsy~5. Subjects with cardiovascular disease~6. Subjects whose hemoglobin is below the lower limit of normal~7. Subjects with a history or possibility of a difficult airway~8. Abnormal liver function and/or abnormal renal function~9. Adrenoceptor agonists or antagonists or analgesics were used before randomization~10. Participated in clinical trials (received experimental drugs)~11. History of hypersensitivity to drug ingredients or components~12. Other circumstances that the investigator judged inappropriate for participation in this clinical trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine Hydrochloride Nasal Spray (Type: EXPERIMENTAL): None
- Dexmedetomidine hydrochloride nasal spray blank preparation (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 30-80~* Idiopathic PD Hoehn \& Yahr stage 2-4,~* diagnosed by 2 of the 3 cardinal motor features~* Fluctuation response to levodopa~* Dyskinesia~* No other historical, laboratory or physical signs to suggest an alternate diagnosis~* No significant dementia, MMSE\>24~* On oral levodopa therapy~Exclusion Criteria:~* dementia~* psychosis~* severe anxiety~* unstable cardiovascular disease~* uncontrolled hypertension~* history of cardiac arrhythmias~* active peptic ulcer disease~* anemia (HCT\<32%)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are capable of understanding and complying with protocol requirements in the opinion of the investigator or the sub-investigator.~2. Patients who are able to fill in the informed consent form.~3. Patients who require gastrointestinal endoscopy using a scope of 9mm or greater diameter for follow-up of confirmed or investigation of a suspected upper gastrointestinal disease. (except for transnasal endoscopy and emergency endoscopy)~4. Male or female chinese patients aged _18_ to _80~5. Patients who agree to use routinely adequate contraception from signing of informed consent to follow-up.~Exclusion Criteria:~1. Patients have received any investigational drug of other study within 120 days prior to providing their informed consent.~2. Patients had been administered NPO-11 in the past.~3. Patients who are the study site investigator or sub-investigator, an immediate family member (eg, spouse,parent, child, sibling), or may consent under duress.~4. Patients have a history of upper gastrointestinal tract surgery.~5. Patients have gastric stenosis or deformity that would make observation of peristaltic movement difficult.~6. Patients have bleeding in the upper gastrointestinal tract and require hemostatic intervention.~7. Patients have reflux esophagitis (defined as Los Angeles Class: B, C or D)~8. Patients have an active gastric or duodenal ulcer (defined as Sakita-Miwa class: A1 or A2)~9. Patients are on treatment (radiotherapy or chemotherapy) for cancer.~10. Patient have decreased heart function (NYHA heart function class: III or more)~11. Patients have a history of shock, hypersensitivity or allergies to l-menthol or peppermint oil.~12. Patients have a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 12 months prior to the screening visit.~13. Patients are required to take excluded medications.~14. If female, patients are pregnant or lactating or intending to become pregnant from signing of informed consent to follow-up.~15. Any subject who, in the opinion of the investigator or the sub-investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NPO-11 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant patients 18 years and older~2. Singleton gestation~3. Pregnancy managed at Lucile Packard Children's Hospital (LPCH) Stanford outpatient obstetrics clinic~4. Planned delivery at Lucile Packard Children's Hospital (LPCH) Stanford Labor and Delivery unit~Exclusion Criteria:~1. Pregestational diabetes~2. Gestational diabetes diagnosed in the 1st trimester~3. Less than 18 years of age~4. Planned delivery outside LPCH~5. Diabetes medication use prior to pregnancy~6. Inability to give informed consent~7. Chronic steroid use in pregnancy~8. Less than 24 weeks of gestation at the time of the 1 hour oral glucose tolerance test~9. Prior history of bariatric surgery~10. Multifetal gestation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fasting before gestational diabetes screen (Type: EXPERIMENTAL): Fasting for at least 6 hours prior to the 1-hour gestational diabetes screen.
- Fed before gestational diabetes screen (Type: ACTIVE_COMPARATOR): Liberal per oral intake within 2 hours of the 1-hour gestational diabetes screen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete